Dr Paul Fineran
Dr Paul Fineran carried out his PhD in Pharmacology at the University of Oxford. His research was concerned with a potential mechanistic link between the common infectious disorder Tuberculosis and the cellular pathways underlying a rare human genetic disease called Niemann-Pick Disease Type C.
Following his PhD Paul helped to establish and run an Oxford-based biotech focused on developing therapies, predicated on small-molecule modulation of lysosomal function, for a range of rare and common diseases. Here he gained expertise in research and project management, intellectual property, and regulatory pathways.
Paul’s experience in the rare disease field, during which he worked closely with patient groups and with clinicians, has reinforced his desire to help translate academic research into real-world impact.